AbbVie News

Abbvie wins another bellwether trial amid mass action over Androgel testosterone drug

By Jonathan Bilyk | Jun 15, 2018

A federal jury has handed a win to North Chicago-based drugmaker Abbvie, as it continues to seek to fend off a mass of legal claims accusing the company’s testosterone replacement therapy drug, Androgel, of causing heart attacks and other cardiovascular conditions.

Drug maker AbbVie wants to slip from $140M verdict, says jury ignored evidence

By Dan Churney | Nov 6, 2017

North Chicago-based drug company AbbVie is urging a federal judge to trash a verdict ordering it to cough up $140 million, because its testosterone therapy drug AndroGel contributed to a man's heart attack, contending it has no liability because AndroGel was approved by the FDA.

Judge: Testosterone replacement drug bellwether OK to proceed vs Testim maker Auxilium

By Jonathan Bilyk | Oct 24, 2017

After two federal juries delivered $140 million verdicts against AbbVie, competing drugmaker Auxilium will be headed to trial over claims its testosterone replacement therapy drug Testim caused heart attacks in men who took the drug to treat “off-label” conditions, spurred by what plaintiffs alleged was misleading marketing from drugmakers.

Investors allowed to continue pursuing AbbVie in Cook Co court over cancelled Shire acquisition

By Scott Holland | Oct 16, 2017

A group of investor funds will be allowed to continue their fraudulent concealment lawsuit against drugmaker AbbVie in Cook County Circuit Court after a federal judge in Chicago shot down AbbVie’s attempt to relocate to federal jurisdiction the lawsuit over AbbVie's cancelled acquisition of an Irish pharmaceutical company.

Jury: AbbVie should pay $150M for Androgel marketing; AbbVie: Verdict won't stand

By Jonathan Bilyk | Jul 24, 2017

A federal jury has ordered drugmaker AbbVie to pay $150 million in damages for allegedly falsely marketing the benefits of its Androgel testosterone therapy drug, even though the jury did not hold the company liable for a heart attack suffered by a man taking the drug.

Federal judge tosses some accusations vs testosterone drug makers on eve of Androgel bellwether trials

By Dan Churney | May 16, 2017

A Chicago federal judge has dismissed several. but not all of the claims against the maker of a testosterone boosting drug, advanced by several plaintiffs chosen as bellwethers in a class-action lawsuit brought by more than 2,000 plaintiffs from around the U.S. against multiple drug manufacturers, including Besins, AbbVie, Eli Lilly and GlaxoSmithKline.

Judge tosses insurers' RICO class action vs testosterone drug makers, saying not specific enough

By Jonathan Bilyk | Feb 4, 2016

A federal judge has tossed, with leave to amend, the bulk of a federal racketeering and fraud class action brought by an Ohio-based health insurer against Abbvie and other makers of testosterone drugs, saying the insurer has not yet backed up with enough particularity its allegations the drugmakers invented the condition known as “low T,” and, through false marketing to doctors, patients and insurers alike, induced insurers and others to pay far more for the drugs to treat the condition.

The Record Network